Kirill Ostanin, PhD
Senior Director, Biochemistry
A protein biochemist by training, Kirill has been involved in industrial drug discovery for over two decades. After graduating with a doctorate degree in Biology from St. Petersburg State University, Russia, Kirill performed postdoctoral work in the Department of Chemistry at Purdue University. The earliest stages of his industrial career at Cadus and OSI on East Coast yielded patented contributions to innovative drug screening technologies for G protein-coupled receptors. After moving to Salt Lake Valley in 2000, Kirill led the Biochemistry groups at Myrexis (then Myriad Pharmaceuticals) and more recently at Navigen, as well as served as project director, lead biologist or principal biochemist in multidisciplinary drug discovery project teams in diverse therapeutic areas including cancer, rheumatoid arthritis, age-related macular degeneration and cardiovascular disease. His work at Navigen Pharmaceuticals, in collaboration with the academic laboratory of Dr. Dean Li, a co-founder of both Navigen and Recursion, led to identification of first-in-class inhibitors of small GTPase Arf6 with demonstrated therapeutic potential for a broad spectrum of vascular disorders. Kirill’s highest priorities outside of work include various outdoor activities with his wolfish dog.